Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma

Published:2024-09-03 Issue: Volume: Page:1-15
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Reece Donna¹,Diels Joris²^ORCID,Van Sanden Suzy²,Pei Lixia³,Ammann Eric⁴,Heuck Christoph⁵,Kane Colleen⁵,Londhe Anil⁶,Peterson Steve⁷,Chari Ajai⁸

Affiliation:

1. Princess Margaret Cancer Centre, Toronto, ON, Canada

2. Janssen Pharmaceutica NV, Beerse, Belgium

3. Janssen Research & Development, Raritan, NJ, USA

4. Janssen Global Services, Raritan, NJ, USA

5. Janssen Research & Development, Spring House, PA, USA

6. Janssen Research & Development, Titusville, NJ, USA

7. Janssen Research & Development, Horsham, PA, USA

8. University of California, San Francisco, San Francisco, CA, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2024.2391553

Reference30 articles.

1. Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management

2. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

3. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

4. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

5. Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression